KLOW is a single 80 mg lyophilized vial containing four compounds: GHK-Cu, BPC-157, TB-500 and KPV. GHK-Cu is the predominant component; exact proportions for the vial you receive are printed on that lot's certificate of analysis.

Each component is assayed by HPLC-UV at 220 nm for purity under USP , identity is confirmed by FTIR under USP , and bacterial endotoxin is measured by gel-clot LAL under USP . Testing is performed by an accredited third-party laboratory, not in house.

Why are these four compounds combined?

Each has been studied in a different part of the matrix-remodelling and inflammatory-signalling literature — copper transport and matrix remodelling, angiogenic and gastrointestinal models, actin sequestration, and melanocortin-pathway inflammatory signalling. Combining them into one vial is a formulation convenience for researchers designing multi-component protocols; it is not evidence of a combined effect.

Is KLOW for human use?

No. KLOW is supplied for research use only and is not for human or veterinary use.

Sequence	Aib-His-D-2Nal-D-Phe-Lys-NH₂
Length	5 residues
Formula	C₃₈H₄₉N₉O₅
Mol. weight	711.86 g/mol
CAS	170851-70-4
PubChem	9831659

Neuroendocrine

Ipamorelin

Ipamorelin is a synthetic pentapeptide growth-hormone-releasing peptide (GHRP) developed at Novo Nordisk in the late 1990s. It is characterized in the literature as a selective GH secretagogue with limited ACTH, cortisol, and prolactin response reported in pre-clinical models.

Molecular structure

Sequence Aib-His-D-2Nal-D-Phe-Lys-NH₂

What it has been studied for

Research interest centers on the ghrelin-receptor (GHS-R1a) axis and selective GH-pulse studies. The peptide has been investigated in models of growth-hormone insufficiency, post-operative recovery research, and metabolic studies.

References

Citations for this compound are being verified against the primary sources before they are listed. Nothing appears here until it has been checked.

Back to Ipamorelin

For Research Use Only. Not for human or veterinary use.